[HTML][HTML] 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human …
C Kratochwil, FL Giesel, F Bruchertseifer… - European journal of …, 2014 - Springer
C Kratochwil, FL Giesel, F Bruchertseifer, W Mier, C Apostolidis, R Boll, K Murphy…
European journal of nuclear medicine and molecular imaging, 2014•SpringerPurpose Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter
such as 90 Y/177 Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer.
Alternative treatments for patients with refractory disease are rare. Here we report the first-in-
human experience with 213 Bi-DOTATOC targeted alpha therapy (TAT) in patients
pretreated with beta emitters. Methods Seven patients with progressive advanced
neuroendocrine liver metastases refractory to treatment with 90 Y/177 Lu-DOTATOC were …
such as 90 Y/177 Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer.
Alternative treatments for patients with refractory disease are rare. Here we report the first-in-
human experience with 213 Bi-DOTATOC targeted alpha therapy (TAT) in patients
pretreated with beta emitters. Methods Seven patients with progressive advanced
neuroendocrine liver metastases refractory to treatment with 90 Y/177 Lu-DOTATOC were …
Purpose
Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter such as 90Y/177Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer. Alternative treatments for patients with refractory disease are rare. Here we report the first-in-human experience with 213Bi-DOTATOC targeted alpha therapy (TAT) in patients pretreated with beta emitters.
Methods
Seven patients with progressive advanced neuroendocrine liver metastases refractory to treatment with 90Y/177Lu-DOTATOC were treated with an intraarterial infusion of 213Bi-DOTATOC, and one patient with bone marrow carcinosis was treated with a systemic infusion of 213Bi-DOTATOC. Haematological, kidney and endocrine toxicities were assessed according to CTCAE criteria. Radiological response was assessed with contrast-enhanced MRI and 68Ga-DOTATOC-PET/CT. More than 2 years of follow-up were available in seven patients.
Results
The biodistribution of 213Bi-DOTATOC was evaluable with 440 keV gamma emission scans, and demonstrated specific tumour binding. Enduring responses were observed in all treated patients. Chronic kidney toxicity was moderate. Acute haematotoxicity was even less pronounced than with the preceding beta therapies.
Conclusion
TAT can induce remission of tumours refractory to beta radiation with favourable acute and mid-term toxicity at therapeutic effective doses.
Springer